Pharmaceutical companies have focused few resources toward developing novel drugs for treating disorders of brain development for a variety of scientific, drug development and economic reasons. Seaside Therapeutics was founded to fill this void and will focus on developing treatments for these disorders. Recent discoveries by Seaside Therapeutics scientific founder, Mark Bear, revealed biochemical deficits associated with fragile X syndrome (FXS) that suggested the possibility of novel therapeutics. FXS is a genetically inherited disorder of brain development and is the most common known genetic cause of autism. We identified a class of compounds that were able to modulate the abnormal processing and licensed several advanced drug candidates from Merck & Co., Inc.

Our lead compound, STX107, has demonstrated efficacy in animal models of FXS. Because, FXS is a rare medical condition, development of STX107 is likely to qualify for collaborative FDA protocol assistance under the Orphan Drug Act. We believe this access to FDA assistance will facilitate design of research that conforms to FDA requirements and thereby shorten the usual timelines for FDA drug approval.

In addition to STX107, the Seaside Therapeutics team is investigating additional novel treatments that we believe will provide meaningful benefit to individuals with disorders of brain development.

Next: Our Mission »